Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

4.3%

1 terminated/withdrawn out of 23 trials

Success Rate

91.7%

+5.2% vs industry average

Late-Stage Pipeline

61%

14 trials in Phase 3/4

Results Transparency

9%

1 of 11 completed trials have results

Key Signals

3 recruiting1 with results

Enrollment Performance

Analytics

Phase 3
7(36.8%)
Phase 4
7(36.8%)
Phase 2
3(15.8%)
N/A
2(10.5%)
19Total
Phase 3(7)
Phase 4(7)
Phase 2(3)
N/A(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (23)

Showing 20 of 23 trials
NCT07052162Phase 4Recruiting

Investigating the Pharmacokinetics of Tafenoquine in Healthy Papua New Guinean Children

Role: collaborator

NCT07060404Phase 2Not Yet Recruiting

Postpartum 8-aminoquinoline Breast Milk Study

Role: collaborator

NCT07468526Phase 3Not Yet Recruiting

An Ultra-short Course of Primaquine for the Radical Cure of Vivax Malaria

Role: collaborator

NCT07468513Phase 4Recruiting

Primaquine for Vivax Malaria in G6PD Intermediate and Deficient Cases.

Role: collaborator

NCT07403643Phase 4Not Yet Recruiting

Investigating the Pharmacology of Tafenoquine in Papua New Guinean Children With Uncomplicated Malaria

Role: collaborator

NCT05874271Not ApplicableCompleted

Short Course Primaquine for the Radical Cure of P. Vivax - Papua New Guinea

Role: collaborator

NCT06148792Phase 3Recruiting

A Revised Tafenoquine Dose to Improve Radical Cure for Vivax Malaria

Role: collaborator

NCT05426434Phase 3Active Not Recruiting

Sulfadoxine-pyrimethamine Plus Dihydroartemisinin-piperaquine for Intermittent Preventive Treatment in Pregnancy

Role: collaborator

NCT04183322Completed

PCV13 in Non-pregnant Papua New Guinean Women

Role: collaborator

NCT03268252Completed

Optimization of MDA With Existing Drug Regimens for LF: Monitoring Efficacy of Ongoing Treatment Programs in PNG

Role: collaborator

NCT02344628Phase 3Completed

Comparison of Two Different Doses of Azithromycin for Treatment of Yaws

Role: collaborator

NCT03462615Unknown

Clinical Performance of the Histidine Rich Protein 2 (HRP2) Highly Sensitive Rapid Diagnostic Test (HS-RDT) for Malaria Diagnosis in Pregnant Women in Papua New Guinea

Role: collaborator

NCT02605720Phase 3Completed

Cardiac Safety of Repeated Doses of Dihydroartemisinin-Piperaquine for the Use in Mass Treatment Campaigns

Role: collaborator

NCT02575755Phase 4Unknown

A Safety, Tolerability, Pharmacokinetic and Efficacy Study of Azithromycin Plus Piperaquine as Presumptive Treatment in Pregnant PNG Women

Role: lead

NCT02364583Phase 4Unknown

Investigation of Short Course, High Dose Primaquine Treatment for Liver Stages of Plasmodium Vivax Infection

Role: lead

NCT01841203Completed

Dual Point-of-care Test for the Diagnosis of Yaws

Role: collaborator

NCT02143934Phase 4Completed

Effect of Liver and Blood-stage Treatment on Subsequent Plasmodium Reinfection and Morbidity

Role: lead

NCT01619462Phase 3Unknown

Safety and Immunogenicity of 10-valent and 13-valent Pneumococcal Conjugate Vaccines in Papua New Guinean Children

Role: lead

NCT01136850Phase 3Completed

Intermittent Preventive Treatment With Azithromycin-containing Regimens in Pregnant Women in Papua New Guinea

Role: collaborator

NCT01599000Phase 4Completed

Artemether-Lumefantrine Clinical Effectiveness Study

Role: lead